Reverse cholesterol transport fluxes

Current Opinion in Lipidology

Volumn 25, Issue 1, 2014, Pages 40-47

  Hellerstein, Marc ^a,b,c   Turner, Scott ^a  

^a KINEMED INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

flux; HDL; lipoproteins; reverse cholesterol transport

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; EZETIMIBE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; SERUM ALBUMIN;

ALBUMIN BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL FLUX; CHOLESTEROL TRANSPORT; CLINICAL STUDY; EFFUSION; ERYTHROCYTE; HUMAN; HYPOALPHALIPOPROTEINEMIA; NONHUMAN; PRIORITY JOURNAL; REVERSE CHOLESTEROL TRANSPORT; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

ARTHRITIS, RHEUMATOID; AZETIDINES; BIOLOGICAL TRANSPORT; CHOLESTEROL; FENOFIBRATE; HUMANS; HYPOALPHALIPOPROTEINEMIAS;

EID: 84893013430     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000050     Document Type: Review

References (32)

1. Glomset JA. The plasma lecithins:cholesterol acyltransferase reaction. J Lipid Res 1968; 9:155-167.
2. Fisher EA, Feig JE, Hewing B, et al. High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2012; 32:2813-2820.
3. Rosenson RS, Brewer HB Jr, Davidson WS, et al. Cholesterol efflux and atheroprotection: Advancing the concept of reverse cholesterol transport. Circulation 2012; 125:190-191
4. Groen AK, Oude Elferink RP, Verkade HJ, Kuipers F. The ins and outs of reverse cholesterol transport. Ann Med 2004; 36:135-145.
5. Brufau G, Groen AK, Kuipers F. Reverse cholesterol transport revisited: Contribution of biliary versus intestinal cholesterol excretion. Arterioscler Thromb Vasc Biol 2011; 31:1726-1733.
6. Rousset X, Shamburek R, Vaisman B, et al. Lecithin cholesterol acyltransferase: An anti or pro-atherogenic factor? Curr Atheroscler Rep 2011; 13:249-256.
7. Khera AV, Rader DJ. Cholesterol efflux capacity: Full steam ahead or a bump in the road? Arterioscler Thromb Vasc Biol 2013; 33:1449-1451.
8. Li XM, Tang WH, Mosior MK, et al. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol 2013; 33:1696-1705.
9. RothblatGH, Phillips MC. High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipidol 2010; 21:229-238.
10. van der Wulp MY, Verkade HJ, Groen AK. Regulation of cholesterol homeostasis. Mol Cell Endocrinol 2013; 368:1-16.
11. deGoma EM, deGoma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol 2008; 51:2199-2211.
12. Tall AR, Yvan-Charvet L, Terasaka N, et al. HDL, ABC transporters, and cholesterol efflux: Implications for the treatment of atherosclerosis. Cell metabolism 2008; 7:365-375.
13. Goodman DS, Noble RP, Dell RB. Three-pool model of the long-term turnover of plasma cholesterol in man. J Lipid Res 1973; 14:178-188.
14. Goodman DS, Smith FR, Seplowitz AH, et al. Prediction of the parameters of whole body cholesterol metabolism in humans. J Lipid Res 1980; 21:699-713.
15. Goldberg IJ, Holleran S, Ramakrishnan R, et al. Lack of effect of lovastatin therapy on the parameters of whole-body cholesterol metabolism. J Clin Investig 1990; 86:801-808.
16. Schwartz CC, Zech LA, VandenBroek JM, Cooper PS. Cholesterol kinetics in subjects with bile fistula. Positive relationship between size of the bile acid precursor pool and bile acid synthetic rate. J Clin Investig 1993; 91:923-938.
17. Schwartz CC, VandenBroek JM, Cooper PS. Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans. J Lipid Res 2004; 45:1594-1607.
18. Turner S, Voogt J, Davidson M, et al. Measurement of reverse cholesterol transport pathways in humans: In vivo rates of free cholesterol efflux, esterification, and excretion. J Am Heart Assoc 2012; 1:e00182
19. Davidson MH, Voogt J, Luchoomun J, et al. Inhibition of intestinal cholesterol absorption with ezetimibe increases components of reverse cholesterol transport in humans. Atherosclerosis 2013; 230:322-32
20. Holleboom AG, Jakulj L, Franssen R, et al. In vivo tissue cholesterol efflux is reduced in carriers of a mutation in APOA1. J Lipid Res 2013; 54:1964-197
21. Cuchel M, Billheimer JT, Millar JS, et al. Assessment of reverse cholesterol transport in vivo in humans: A novel method. Arterioscler Thromb Vasc Biol 2013; 32:A7
22. Jakulj L. Intestinal cholesterol transport: Measuring absorption and is reverse [master's thesis]. Amsterdam, the Netherlands: University of Amsterdam The author demonstrates an effect of ezetmibe on TICE and describes a novel method for determining the flux of cholesterol directly into the gut in humans
23. Tietge UJ, Groen AK. Role the TICE? Advancing the concept of transintestinal cholesterol excretion. Arterioscler Thromb Vasc Biol 2013; 33:1452-1453.
24. Temel RE, Brown JM. Biliary and nonbiliary contributions to reverse cholesterol transport. Curr Opin Lipidol 2012; 23:85-90.
25. Vrins CL, Ottenhoff R, van den Oever K, et al. Trans-intestinal cholesterol efflux is not mediated through high density lipoprotein. J Lipid Res 2012; 53:2017-2023.
26. Hung KT, Berisha SZ, Ritchey BM, et al. Red blood cells play a role in reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2012; 32:1460-146
27. Sankaranarayanan S, de la Llera-Moya M, Drazul-Schrader D, et al. Serum albumin acts as a shuttle to enhance cholesterol efflux from cells. J Lipid Res 2013; 54:671-676.
28. Diditchenko S, Gille A, Pragst I, et al. Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux. Arterioscler Thromb Vasc Biol 2013; 33:2202-221
29. Hoang A, Drew BG, Low H, et al. Mechanism of cholesterol efflux in humans after infusion of reconstituted high-density lipoprotein. Eur Heart J 2012; 33:657-66
30. Charles-Schoeman C, Fleischmann RM, Davignon J, et al. Effects of tofacitinib on lipid profiles and cholesterol and lipoprotein kinetics in patients with rheumatoid arthritis. Arthritis Rheum 2012; 64:555
31. Turner S, Beysen C, Charles-Schoemann C, et al. Increased selective clearance of cholesteryl-ester in patients with rheumatoid arthritis is reversed by treatment with tofacitinib. Arterioscler Thromb Vasc Biol 2013; 33:A124.
32. Dunbar RL, Cuchel M, Millar JS, et al. Niacin does not accelerate reverse cholesterol transport in man. Arterioscler Thromb Vasc Biol 2013; 33:A43